LifeStance Health Group Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
LFST$13.77+2.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except for par value)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| CURRENT ASSETS | ||
| Cash and cash equivalents | $102,615 | $78,824 |
| Patient accounts receivable, net | 158,161 | 125,405 |
| Prepaid expenses and other current assets | 26,244 | 21,502 |
| Total current assets | 287,020 | 225,731 |
| NONCURRENT ASSETS | ||
| Property and equipment, net | 169,974 | 188,222 |
| Right-of-use assets | 154,835 | 170,703 |
| Intangible assets, net | 195,352 | 221,072 |
| Goodwill | 1,293,346 | 1,293,346 |
| Other noncurrent assets | 7,414 | 10,895 |
| Total noncurrent assets | 1,820,921 | 1,884,238 |
| Total assets | $2,107,941 | $2,109,969 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $7,282 | $7,051 |
| Accrued payroll expenses | 111,858 | 102,478 |
| Other accrued expenses | 43,291 | 35,012 |
| Contingent consideration | 2,500 | 8,169 |
| Operating lease liabilities, current | 48,959 | 46,475 |
| Other current liabilities | 3,624 | 3,688 |
| Total current liabilities | 217,514 | 202,873 |
| NONCURRENT LIABILITIES | ||
| Long-term debt, net | 279,055 | 280,285 |
| Operating lease liabilities, noncurrent | 158,679 | 181,357 |
| Deferred tax liability, net | 15,219 | 15,572 |
| Other noncurrent liabilities | 381 | 952 |
| Total noncurrent liabilities | 453,334 | 478,166 |
| Total liabilities | $670,848 | $681,039 |
| COMMITMENTS AND CONTINGENCIES (see Note 12) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock – par value $0.01 per share; 25,000 shares authorized as of September 30, 2024 and December 31, 2023; 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — |
| Common stock – par value $0.01 per share; 800,000 shares authorized as of September 30, 2024 and December 31, 2023; 382,640 and 378,725 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 3,826 | 3,789 |
| Additional paid-in capital | 2,243,673 | 2,183,684 |
| Accumulated other comprehensive income | 771 | 2,303 |
| Accumulated deficit | (811,177) | (760,846) |
| Total stockholders' equity | 1,437,093 | 1,428,930 |
| Total liabilities and stockholders’ equity | $2,107,941 | $2,109,969 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.